A microvascular myocardial infarction in a 16-year-old girl with antiphospholipid syndrome: a case report

Acta Clinica Belgica
Jean-Philippe RigaAlain Friart

Abstract

Objective and importance: The antiphospholipid syndrome can manifest itself by silent (or not) myocardial infarction. Clinical presentation: We report the case of a 16-year-old girl who presented a myocardial infarction for whom a coronary-computer tomography did not reveal any coronary abnormalities or obstruction. She had a livedo reticularis on her physical exam. Intervention: The echocardiography showed a normal left ventricular function and a mild eccentric mitral regurgitation. A myocardial magnetic resonance imaging demonstrated transmural necrosis with microvascular obstruction at the inferobasal segment of the left ventricle, suggestive of a microvascular myocardial infarction. The blood test showed elevation of the three antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein). The lupus anticoagulant remained positive 12 weeks later, fulfilling the laboratory criteria for antiphospolipid carrier. The associated presence of this microvascular coronary obstruction was strongly suggestive of antiphospholipd syndrome, according to the revised Sapporo criteria. To our knowledge, this is the first reported case of antiphospholipid syndrome manifesting as an acute microvascular myocardial...Continue Reading

References

Jun 4, 2005·Arthritis and Rheumatism·Camille FrancèsJean Charles Piette
Sep 9, 2010·Lancet·Guillermo Ruiz-IrastorzaMunther A Khamashta
Dec 3, 2014·Autoimmunity Reviews·Gentian DenasVittorio Pengo
Dec 24, 2014·Autoimmunity Reviews·Cristina Belizna
Sep 14, 2015·European Heart Journal·Giampaolo NiccoliFilippo Crea
Mar 7, 2017·Thrombosis Research·Ricard Cervera

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.